drug
octreotide acetate DR
Marketedupdated 5mo agoby Chiasma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- drugoctreotide LA4 co-mentions · 4 sources
- drugoctreotide acetate4 co-mentions · 4 sources
- drugoctreotide acetate LA4 co-mentions · 4 sources
- drugBynfezia4 co-mentions · 4 sources
- companyTeva Pharmaceuticals USA Inc3 co-mentions · 3 sources
- tagRecall3 co-mentions · 3 sources
- tagApproval2 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying octreotide acetate DR
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 26, 2027
267 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (21)
- Dec 29, 2041method-of-use (U-4009)US 12350475
- Dec 28, 2040method-of-use (U-3232)US 11141457
- Dec 28, 2040method-of-use (U-3232)US 11890316
- Nov 3, 2040method-of-use (U-4009)US 11052196
- Nov 3, 2040method-of-use (U-4009)US 11246991
- Nov 3, 2040method-of-use (U-4009)US 11534553
- May 15, 2038formulationUS 10342850
- Feb 3, 2036method-of-use (U-2857)US 10238709
- Feb 3, 2036method-of-use (U-2857)US 10695397
- Feb 3, 2036method-of-use (U-2857)US 11052126
- Feb 3, 2036method-of-use (U-2857)US 11338011
- Feb 3, 2036method-of-use (U-2857)US 11510963
- Feb 3, 2036method-of-use (U-3784)US 11857595
- Feb 3, 2036method-of-use (U-2857)US 12246054
- Feb 3, 2036method-of-use (U-2857)US 12251418
- Sep 17, 2029formulationUS 119694713.0y
- Sep 17, 2029method-of-use (U-2857)US 119865293.0y
- Sep 17, 2029formulationUS 83291983.0y
- Sep 17, 2029method-of-use (U-2857)US 85356953.0y
- Sep 17, 2029formulationUS 92658123.0y
- Sep 17, 2029formulationUS 95662463.0y
FDA exclusivities (4)
- Jun 26, 2027ODE-474Orphan Drug (7y)267d
- Aug 2, 2026CGTCGT
- Jul 27, 2026CGTCGT
- Jul 27, 2026CGTCGT
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that